24.02
-0.33 (-1.36%)
| Previous Close | 24.35 |
| Open | 24.21 |
| Volume | 438,442 |
| Avg. Volume (3M) | 553,595 |
| Market Cap | 1,436,336,000 |
| Price / Sales | 650.22 |
| Price / Book | 6.53 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Diluted EPS (TTM) | -37.90 |
| Total Debt/Equity (MRQ) | 0.06% |
| Current Ratio (MRQ) | 7.32 |
| Operating Cash Flow (TTM) | -151.25 M |
| Levered Free Cash Flow (TTM) | -60.86 M |
| Return on Assets (TTM) | -38.80% |
| Return on Equity (TTM) | -91.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Spyre Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | 1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.10 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.98% |
| % Held by Institutions | 87.64% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (Baird, 170.61%) | Buy |
| 65.00 (Guggenheim, 170.61%) | Buy | |
| Median | 65.00 (170.61%) | |
| Average | 65.00 (170.61%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 33.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 13 Nov 2024 | 65.00 (170.61%) | Buy | 32.98 |
| Guggenheim | 25 Oct 2024 | 65.00 (170.61%) | Buy | 34.81 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |